Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1572913 | 0.91 | PTGS2 (0.57) | PTGS2PTGS1 | |
| SCHEMBL2086108 | 0.90 | PTGS2 (0.51) | PTGS2PTGS1 | |
| SCHEMBL2084273 | 0.90 | PTGS2 (0.46) | PTGS2PTGS1 | |
| SCHEMBL3397783 | 0.88 | PTGS2 (0.40) | PTGS2PTGS1 | |
| SCHEMBL13017938 | 0.88 | PTGS2 (0.40) | PTGS2PTGS1 | |
| SCHEMBL2084657 | 0.88 | PDE4A (0.44) | PTGS2PTGS1 | |
| SCHEMBL1573022 | 0.83 | ADORA1 (0.39) | PTGS2 | |
| SCHEMBL27750163 | 0.83 | PTGS2 (0.32) | PTGS2PTGS1 | |
| SCHEMBL13744894 | 0.82 | SMN1; SMN2 (0.36) | PTGS2PTGS1 | |
| SCHEMBL1573242 | 0.82 | PTGS2 (0.50) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1973884-B1 | NOVEL HETEROCYCLES | ORCHID PHARMA LTD (IN) | 2016-08-03 | — | — | EP | disclosed |
| EP-1973884-B1 | NOVEL HETEROCYCLES | ORCHID PHARMA LTD (IN) | 2016-08-03 | — | — | EP | disclosed |
| US-20140272398-A1 | TRANSPARENT ELECTRODE AND ELECTRONIC DEVICE | Konica Minolta, Inc. (JP) | 2014-09-18 | — | — | US | disclosed |
| US-8828999-B2 | Pyrimidine compounds and their uses | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2014-09-09 | — | — | US | disclosed |
| US-8828999-B2 | Pyrimidine compounds and their uses | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2014-09-09 | — | — | US | disclosed |
| US-20130172350-A1 | PYRIMIDINE COMPOUNDS AND THEIR USES | ORCHID CHEMICALS AND PHARMACEUTICALS LIMITED (IN) | 2013-07-04 | — | — | US | disclosed |
| US-20130172350-A1 | PYRIMIDINE COMPOUNDS AND THEIR USES | ORCHID CHEMICALS AND PHARMACEUTICALS LIMITED (IN) | 2013-07-04 | — | — | US | disclosed |
| US-8420653-B2 | Pyrimidine compounds and their uses | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2013-04-16 | — | — | US | disclosed |
| US-8420653-B2 | Pyrimidine compounds and their uses | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2013-04-16 | — | — | US | disclosed |
| US-7863446-B2 | Heterocycles | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2011-01-04 | — | — | US | disclosed |
| US-20100329998-A1 | NOVEL HETEROCYCLES | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2010-12-30 | — | — | US | disclosed |
| EP-2245017-A2 | NOVEL HETEROCYCLES | Orchid Research Laboratories Limited (IN) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009095773-A2 | NOVEL HETEROCYCLES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2009-08-06 | — | — | WO | disclosed |
| EP-1973884-A2 | NOVEL HETEROCYCLES | Orchid Research Laboratories Limited (IN) | 2008-10-01 | — | — | EP | disclosed |
| US-20080207606-A1 | Novel heterocycles | ORCHID RESEARCH LABORATORIES LIMITED. (IN) | 2008-08-28 | — | — | US | disclosed |
| WO-2007083182-A2 | NOVEL HETEROCYCLES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2007-07-26 | — | — | WO | disclosed |
| US-20070167413-A1 | Novel heterocycles | ORCHID RESEARCH LABORATORIES LIMITED. (IN) | 2007-07-19 | — | — | US | disclosed |
| US-20070167413-A1 | Novel heterocycles | ORCHID RESEARCH LABORATORIES LIMITED. (IN) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207606-A1 | Novel heterocycles | GPR4, UACA, PDE4A | PTGS2 1346/4885PTGS1 622/4885 |
| US-20100329998-A1 | NOVEL HETEROCYCLES | UACA, GPR4, CASP4 | PTGS2 1482/4885PTGS1 754/4885 |
| US-20070167413-A1 | Novel heterocycles | MCL1, UACA, MYLK2 | PTGS2 1550/4885PTGS1 809/4885 |
| US-20130172350-A1 | PYRIMIDINE COMPOUNDS AND THEIR USES | UMPS, PNP, PDE4A | PTGS2 1485/4885PTGS1 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.